Cargando…

Patient’s experiences with the care for juvenile idiopathic arthritis across Europe

BACKGROUND: To assess the views of juvenile idiopathic arthritis (JIA) patients and their parents on the care and treatment they receive in referral pediatric rheumatology centers throughout Europe. METHODS: In a collaboration between physicians and patient associations, a questionnaire was develope...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dijkhuizen, E. H. Pieter., Egert, Tsipi, Egert, Yona, Costello, Wendy, Schoemaker, Casper, Fernhout, Marlous, Kepic, Mirjam, Martini, Alberto, Scala, Silvia, Rotstein-Grein, Ingrid, Vastert, Sebastiaan J., Wulffraat, Nico M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806356/ https://www.ncbi.nlm.nih.gov/pubmed/29422094 http://dx.doi.org/10.1186/s12969-018-0226-0

Ejemplares similares

Self-management support for young people living with fluctuating chronic diseases
por: Schoemaker, Casper G, et al.
Publicado: (2022)

Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients
por: Schoemaker, Casper G., et al.
Publicado: (2018)

Early predictors of prognosis in juvenile idiopathic arthritis patients: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Prediction of Methotrexate Intolerance in Juvenile Idiopathic Arthritis: a prospective, observational cohort study
por: van Dijkhuizen, Evert Hendrik Pieter, et al.
Publicado: (2015)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
por: Schoemaker, Casper G., et al.
Publicado: (2020)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: van Dijkhuizen, EH Pieter, et al.
Publicado: (2014)

The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Wulffraat, Nico, et al.
Publicado: (2018)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol
por: Schoemaker, Casper G., et al.
Publicado: (2018)

PReS-FINAL-2162: Development of a risk model to predict methotrexate intolerance in juvenile idiopathic arthritis
por: Van Dijkhuizen, P, et al.
Publicado: (2013)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, EH Pieter, et al.
Publicado: (2011)

Share – Workpackage 4: addressing the need for health care for paediatric rheumatic diseases throughout europe
por: Dolezalova, Pavla, et al.
Publicado: (2014)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know
por: Grein, Ingrid Herta Rotstein, et al.
Publicado: (2016)

Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2019)

Share – Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis
por: Vastert, Sebastiaan, et al.
Publicado: (2014)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review
por: Kip, Michelle M. A., et al.
Publicado: (2019)

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
por: Kip, Michelle M A, et al.
Publicado: (2022)

Time to share
por: Wulffraat, Nico M, et al.
Publicado: (2013)

Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis
por: Vastert, SJ, et al.
Publicado: (2008)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis
por: Boom, V., et al.
Publicado: (2015)

PReS-FINAL-2181: Recombinant il-1ra restores the il-18-nk cell axis in steroid naive systemic juvenile idiopathic arthritis
por: De Jager, W, et al.
Publicado: (2013)

Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
por: Kip, Michelle M. A., et al.
Publicado: (2022)

Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study
por: Grazziotin, Luiza R., et al.
Publicado: (2022)

SHARE – workpackage 5: development of best practices of diagnosis and treatment for paediatric rheumatic diseases throughout Europe
por: Vastert, Sebastiaan, et al.
Publicado: (2014)

Feasibility of quantitative sensory testing in juvenile idiopathic arthritis
por: Mensink, Maarten O., et al.
Publicado: (2022)

Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis
por: Grazziotin, Luiza R., et al.
Publicado: (2022)

IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA
por: Vastert, Sebastiaan J, et al.
Publicado: (2012)

Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis
por: Nijhuis, Lotte, et al.
Publicado: (2019)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
por: van Pelt, Philomine A, et al.
Publicado: (2012)

4.5 Defective phosphorylation of the interleukin 18 receptor beta-chain causes impaired NK cell function in systemic onset Juvenile Idiopathic Arthritis
por: de Jager, W, et al.
Publicado: (2008)

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_78cnsf4sagf1770aideh27mqgp